| AHF | Acute heart failure |
| AMP | Adenosine monophosphate |
| ATP | Adenosine triphosphate |
| ATPase | Adenosine triphosphatase |
| cAMP | Cyclic adenosine monophosphate |
| CS | Cardiogenic shock |
| DOREMI | Dobutamine Compared with Milrinone Trial |
| ESC | European Society of Cardiology |
| HF | Heart failure |
| HORIZON-HF | Hemodynamic Effects of Istaroxime in Patients with Heart Failure |
| ICU | Intensive care unit |
| K-ATP | ATP-sensitive potassium channel |
| MCS | Mechanical circulatory support |
| mmHg | Millimeters of mercury |
| NCX | Sodium–calcium exchanger |
| PDE-3 | Phosphodiesterase type 3 |
| PKA | Protein kinase A |
| REVIVE | Randomized Evaluation of Intravenous Levosimendan Efficacy |
| RV | Right ventricle/Right ventricular |
| SCAI | Society for Cardiovascular Angiography and Interventions |
| SEISMiC | Studies of Istaroxime in Cardiogenic Shock |
| SERCA2a | Sarcoplasmic reticulum Ca2+-ATPase isoform 2a |
| SURVIVE | Survival of Patients with Acute Heart Failure in Need of Intravenous Inotropic Support |